Cancer immunotherapy has revolutionized the field of oncology by delivering unprecedented levels of durable survival benefit for cancer patients, including some patients with previously incurable late-stage disease. Anatomic and molecular pathologists have the opportunity to be at the center of the development, validation, and clinical implementation of critically needed cancer immunotherapy biomarkers. This webinar will provide an update on this rapidly evolving field including new clinical data, current and emerging immunotherapy biomarkers, and an exploration of where the field is headed.
- Awareness of the latest cancer immunotherapy clinical data including FDA approvals/changes and combination therapy data.
- Familiarity with current cancer immunotherapy biomarkers such as PD-L1, MMR/MSI and TMB, including their strengths and limitations.
- Awareness of future cancer immunotherapy targets/compounds such as anti-TIGIT and anti-LAG3 including the latest clinical data and the predictive biomarkers being explored.
Eric Walk, MD, FCAP
Jinjuan Yao MD, PhD, FCAP